Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. AZOPT (brinzolamide)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

AZOPT (brinzolamide)

Medicine - Posted on Jan 09 2023
Active substance (DCI)
  • brinzolamide
history (5)
  • 12/14/22

    AZOPT (brinzolamide) - Antiglaucomateux

    Modifications de l’AMM. L'essentiel Avis favorable au maintien de l'inscription sur la liste des spécialités remboursables a...
    icône flèche
  • 9/23/15

    AZOPT (brinzolamide)

    Maintien du remboursement dans les mêmes conditions
    icône flèche
  • 4/28/10

    AZOPT (brinzolamide)

    AZOPT (brinzolamide)
    icône flèche
  • 9/23/09

    AZOPT (brinzolamide)

    AZOPT (brinzolamide)
    CAV :
    54321
    icône flèche
  • 2/15/06

    AZOPT 10 mg/ml, collyre en suspension 1 flacon de 5 ml (CIP : 354 349-7)

    AZOPT 10 mg/ml, collyre en suspension 1 flacon de 5 ml (CIP : 354 349-7)
    icône flèche
Technical information
ATC code
  • S01EC04
Manufacturer
NOVARTIS PHARMA SAS
Presentation

AZOPT 10 mg/ml, collyre en suspension (code CIS : 60868670)
1 flacon compte-gouttes polyéthylène basse densité (PEBD) de 5 ml (CIP : 34009 354 349 7 5)

All our publications
    Drug therapy Eye diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
er06UwYujR3qdweU